It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...

TEWKSBURY, Mass.--(BUSINESS WIRE)--DC Devices, Inc., a medical device company pioneering first-in-class structural heart devices, has closed a $34 million Series D financing round. Accelmed led the ...

Medically reviewed by Jeffrey S. Lander, MD Key Takeaways Heart failure happens when the heart can't pump enough blood ...

Patients were elderly, with a mean (±SD) age of 78 (±7) years and mostly female (58%). About one fifth (17%) of the patients were African Americans. Table I shows that more patients with isolated LVDD ...

Orchestra BioMed Holdings, Inc. announced promising echocardiographic data regarding atrioventricular interval modulation (AVIM) therapy's impact on patients with diastolic dysfunction at the THT 2025 ...

Please provide your email address to receive an email when new articles are posted on . In patients with CKD, isolated diastolic hypertension did not increase risk of adverse cardiovascular and kidney ...

Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis. Arterial stiffness and aortic ...

Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...

A pilot program at a New York hospital designed to help patients manage heart failure after being discharged from the hospital quickly improved patient adherence to their medication and treatment plan ...

Heart failure occurs when the heart can't pump blood as well as it should. It can affect either the left side of the heart (left-sided heart failure) or the right side (right-sided heart failure).

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...